Helicobacter

HPi1 is a selective and orally active antimicrobial against Helicobacter pylori (IC50: 0.24 μM and a MIC of 0.08-0.16 μg/mL). HPi1 is inactive against other Xaliproden, including the gut commensals, Lactobacillus reuteri, Lactobacillus casei, and Bifidoba

Helicobacter pylori alpha-1,3-fucosyltransferase (Hp3FT) catalyzes the glycosylation reaction between the donor GDP-fucose and the acceptor N-acetyllactosamine.

CV-6209 is a potent antagonist of the platelet-activating factor (PAF) receptor.

pNNP (Nitrophenylphosphate) can be used as a substrate for the PP2C assay. pNNP inhibits β-carbonic anhydrase and α-carbonate dehydrogenase, as well as H. pylori Helicobacter pylori. pNNP is a weakly active, tissue-nonspecific alkaline phosphatase modifier. pNNP has been shown to inhibit β-carbonic anhydrase and α-carbonate dehydrogenase.

L-Glutamic acid monosodium salt monohydrate (MSG monohydrate) is an important food additive with gastrointestinal protective effects. It plays a critical role in nutrient metabolism, energy demand, immune response, oxidative stress, signal transduction, and synaptic transmission. L-Glutamic acid monosodium salt monohydrate can induce oxidative stress, DNA damage, and apoptosis in mouse liver and brain tissues. It can protect against gastrointestinal damage caused by NSAIDs and Helicobacter pylori through multiple mechanisms.

Finafloxacin, a fluoroquinolone antimicrobial agent from a new 8-cyano subclass, is most effective in slightly acidic environments (pH 5.0-6.0), a condition where other fluoroquinolones typically reduce in activity. It selectively targets bacterial type II topoisomerases, such as DNA gyrase and DNA topoisomerase IV, making it suitable for treating serious bacterial infections particularly in acidic contexts, including urinary tract infections (UTIs) and Helicobacter pylori infections.

Omeprazole-d3 is a stable deuterated derivative of omeprazole. Omeprazole is a selective proton pump inhibitor (PPI) used in research related to gastrointestinal diseases. Omeprazole inhibits the proliferation and adhesion of Helicobacter pylori and disrupts the stability of the bacterial cell membrane. Omeprazole inhibits the growth of both Gram-positive and Gram-negative bacteria.

FR-145715 is a histamine H2 receptor antagonist characterized by its specific anti-Helicobacter pylori activity. This compound is utilized in the study of gastric lesions.

JAK05 exhibits inhibitory activity against Helicobacter pylori, effectively suppressing strains J63, J196, and J107, with a MIC of 3-5 µg/mL. It shows affinity for binding to H+/K+-ATPase, COX-1/2, TNF-α, and PGE2, and possesses antioxidant and anti-inflammatory properties. In a rat model of ethanol-induced gastric ulcers, JAK05 demonstrates anti-ulcer activity.

BAS-118 is a benzamide derivative exhibiting antibacterial activity. For 100 randomly selected strains of Helicobacter pylori, its MIC50, MIC90, and MIC range were ≤0.003, 0.013, and ≤0.003-0.025 mg/L, respectively. BAS-118 shows potential for research as an anti-H. pylori agent.

Urease-IN-20 (compound XBP2) is an inhibitor of Helicobacter pylori (H. pylori), with an IC50 of 0.14 μM for H. pylori inhibition. It effectively decreases apoptosis in GES-1 cells infected with H. pylori and reduces levels of ROS and γH2AX. Urease-IN-20 also demonstrates significant gastric mucosal protective effects, making it suitable for H. pylori research.

Urease-IN-12 (compound 5e) is a competitive urease inhibitor with an IC50 of 0.35 μM, showing potential in inhibiting gastritis and peptic ulcers caused by Helicobacter pylori.

Antibacterialagent 231 (derivative 8) is an antimicrobial compound effective against multidrug-resistant Helicobacter pylori (H. pylori), with a minimum inhibitory concentration ranging from 0.25 to 0.5 μg/mL. It specifically targets the protein translocase subunit SecA and the outer membrane protein assembly factor BamD to inhibit the transport and assembly of bacterial outer membrane proteins (OMPs). Antibacterialagent 231 is suitable for studying the effects of antibiotic treatment on gut microbiome balance.

Urease-IN-21 (Compound 11b) is a urease inhibitor with an IC50 of 0.12 μM. It exhibits potent antibacterial activity against Helicobacter pylori (H. pylori) and inhibits P450 enzymes (CYP2C19, CYP2C9, and CYP3A4). Urease-IN-21 is applicable in research related to H. pylori infections.

Antibacterialagent 289 (Compound 7c) is an antibacterial agent with potent inhibitory activity against Helicobacter pylori (H. pylori), showing a minimum inhibitory concentration (MIC) of 0.804 μg/mL against H. pylori ATCC 26695 and significant growth inhibition properties. It is applicable in research studies of H. pylori infections.

FabX-IN-1 (Compound 47) is a selective FabX inhibitor with an IC50 of 0.128 μM. It exhibits narrow-spectrum antibacterial activity against Helicobacter pylori, with an MIC of 64 μg/mL. Its synergistic inhibitory effect is significantly enhanced when used in combination with membrane-permeabilizing agents, efflux pump inhibitors, and Clarithromycin. FabX-IN-1 is applicable for bacterial infection research.

Urease/thymidine phosphorylase-IN-1 (compound 8) is an inhibitor of urease and thymidine phosphorylase, with an IC50 of 8.20 μM for urease and 9.29 μM for thymidine phosphorylase. It is applicable in research related to Helicobacter pylori infections, Proteus mirabilis infections, and cancer.

Rifabutin-vonoprazan conjugate 1 is an orally active acid-responsive bifunctional molecule. It exhibits activity against Helicobacter pylori with a minimum inhibitory concentration (MIC) of ≤ 0.125 μg/mL and possesses acid suppression effects with an inhibition rate of over 85% at a dose of 2 mg/kg. Additionally, it has anti-ulcer properties. This compound may be utilized in research related to Helicobacter pylori infections and gastric ulcers.

FR-182024 is a novel cephem derivative, it has potent anti-Helicobacter pylori activity.

Spirolaxine, a natural product isolated from Sporotrichum laxum ATCC 15155, has shown a variety of biological activities including promising anti-Helicobacter pylori property.

4-Amino-6-chloro-1,3-benzenedisulfonamide is a carbonic anhydrase inhibitor.1 Formulations containing this compound are diuretics.2 4-Amino-6-chloro-1,3-benzenedisulfonamide is detected as a hydrolysis product of chlorothiazide in the urine.2 Diuretics, including chlorothiazide, have been abused as performance-enhancing drugs and masking agents in sports doping.3References1. Nishimori, I., Vullo, D., Minakuchi, T., et al. Carbonic anhydrase inhibitors: Cloning and sulfonamide inhibition studies of a carboxyterminal truncated α-carbonic anhydrase from Helicobacter pylori. Bioorg. Med. Chem. Lett. 16(8), 2182-2188 (2006).2. Deventer, K., Pozo, O.J., Van Eenoo, P., et al. Detection of urinary markers for thiazide diuretics after oral administration of hydrochlorothiazide and altizide-relevance to doping control analysis. J. Chromatogr. A 1216(12), 2466-2473 (2009).3. Cadwallader, A.B., de la Torre, X., Tieri, A., et al. The abuse of diuretics as performance-enhancing drugs and masking agents in sport doping: Pharmacology, toxicology and analysis. Br. J. Pharmacol. 161(1), 1-16 (2010). 4-Amino-6-chloro-1,3-benzenedisulfonamide is a carbonic anhydrase inhibitor.1 Formulations containing this compound are diuretics.2 4-Amino-6-chloro-1,3-benzenedisulfonamide is detected as a hydrolysis product of chlorothiazide in the urine.2 Diuretics, including chlorothiazide, have been abused as performance-enhancing drugs and masking agents in sports doping.3 References1. Nishimori, I., Vullo, D., Minakuchi, T., et al. Carbonic anhydrase inhibitors: Cloning and sulfonamide inhibition studies of a carboxyterminal truncated α-carbonic anhydrase from Helicobacter pylori. Bioorg. Med. Chem. Lett. 16(8), 2182-2188 (2006).2. Deventer, K., Pozo, O.J., Van Eenoo, P., et al. Detection of urinary markers for thiazide diuretics after oral administration of hydrochlorothiazide and altizide-relevance to doping control analysis. J. Chromatogr. A 1216(12), 2466-2473 (2009).3. Cadwallader, A.B., de la Torre, X., Tieri, A., et al. The abuse of diuretics as performance-enhancing drugs and masking agents in sport doping: Pharmacology, toxicology and analysis. Br. J. Pharmacol. 161(1), 1-16 (2010).

Zonisamide-13C2,15N is intended for use as an internal standard for the quantification of zonisamide by GC- or LC-MS. Zonisamide (T0267) is an antiepileptic agent.1 It selectively inhibits the repeated firing of sodium channels (IC50 = 2 μg/ml) in mouse embryo spinal cord neurons and inhibits spontaneous channel firing when used at concentrations greater than 10 μg/ml.2 In rat cerebral cortex neurons, zonisamide (1-1,000 μM) inhibits T-type calcium channels with a maximum reduction of 60% of the calcium current.3 Zonisamide (T0267) inhibits H. pylori recombinant carbonic anhydrase (CA) and the human CA isoforms I, II, and V with Ki values of 218, 56, 35, and 21 nM, respectively.4,5 In mice, it has anticonvulsant activity against maximal electroshock seizure (MES) and pentylenetetrazole-induced maximal, but not minimal, seizures (ED50s = 19.6, 9.3, and >500 mg/kg, respectively). Zonisamide (T0267) (40 mg/kg, p.o.) prevents MPTP-induced decreases in the levels of dopamine , but not homovanillic acid or dihydroxyphenyl acetic acid , and increases MPTP-induced decreases in the dopamine turnover rate in mouse striatum in a model of Parkinson's disease.6 Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy.

Cholesterol β-D-Glucoside (β-D-Glucopyranoside) is a toxicant produced by the human parasite Helicobacter pylori.

Lacto-N-biose I, also known as Galβ1-3GlcNAc, is a naturally occurring metabolite that serves as a substrate for the α1,2-fucosyltransferase enzyme derived from Helicobacter pylori[1].